drugset
drugset / Trial / NCT00911898

A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

NCT00911898 ↗

Phase 1 Completed 20 enrolled Merrimack Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label Phase 1 trial of MM-111.

Timeline

Start
2009-06
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject MM-111 Unknown — Intravenous

Indications

breast cancer carcinoma